Brokerages Set Allena Pharmaceuticals Inc (NASDAQ:ALNA) PT at $23.00

Share on StockTwits

Shares of Allena Pharmaceuticals Inc (NASDAQ:ALNA) have been assigned a consensus recommendation of “Buy” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $23.00.

Several brokerages recently issued reports on ALNA. Cowen reiterated a “buy” rating on shares of Allena Pharmaceuticals in a report on Friday, August 9th. Wedbush reiterated an “outperform” rating and set a $36.00 price objective on shares of Allena Pharmaceuticals in a report on Monday, August 12th. Credit Suisse Group cut their price objective on Allena Pharmaceuticals from $26.00 to $7.00 and set an “outperform” rating for the company in a report on Friday, September 6th. ValuEngine raised shares of Allena Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Roth Capital lowered their target price on shares of Allena Pharmaceuticals from $61.00 to $31.00 in a research report on Thursday, August 8th.

Shares of NASDAQ:ALNA traded up $0.05 during midday trading on Thursday, hitting $4.22. 84,100 shares of the stock were exchanged, compared to its average volume of 73,519. The company has a debt-to-equity ratio of 0.22, a quick ratio of 6.80 and a current ratio of 6.80. Allena Pharmaceuticals has a 52-week low of $3.62 and a 52-week high of $11.82. The business’s fifty day simple moving average is $4.10 and its two-hundred day simple moving average is $5.22. The company has a market capitalization of $97.87 million, a PE ratio of -2.45 and a beta of 1.92.

Allena Pharmaceuticals (NASDAQ:ALNA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.01). As a group, equities analysts anticipate that Allena Pharmaceuticals will post -1.98 EPS for the current year.

Institutional investors have recently bought and sold shares of the business. Wedbush Securities Inc. acquired a new position in Allena Pharmaceuticals during the second quarter worth $63,000. Jane Street Group LLC acquired a new position in Allena Pharmaceuticals during the second quarter worth $116,000. Susquehanna International Group LLP acquired a new position in Allena Pharmaceuticals during the second quarter worth $137,000. Deutsche Bank AG increased its position in Allena Pharmaceuticals by 8.2% during the fourth quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock worth $151,000 after buying an additional 2,118 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its position in Allena Pharmaceuticals by 17.0% during the second quarter. Jacobs Levy Equity Management Inc. now owns 41,587 shares of the company’s stock worth $169,000 after buying an additional 6,030 shares during the last quarter. 65.36% of the stock is currently owned by hedge funds and other institutional investors.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

See Also: FAANG Stocks

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.